GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (OTCPK:ZLDPF) » Definitions » Margin of Safety % (DCF FCF Based)

ZLDPF (Zealand Pharma AS) Margin of Safety % (DCF FCF Based) : N/A (As of Dec. 11, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Zealand Pharma AS's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.


Competitive Comparison of Zealand Pharma AS's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Zealand Pharma AS's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Margin of Safety % (DCF FCF Based) falls into.



Zealand Pharma AS Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma AS Business Description

Industry
Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

From GuruFocus

Half Year 2024 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 08-16-2024

Q1 2023 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q4 2021 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 02-15-2024

Zealand Pharma A/S Corporate Call Transcript

By GuruFocus Research 02-15-2024

Q4 2022 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2023 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2022 Zealand Pharma A/S Earnings Call Transcript

By GuruFocus Research 02-15-2024

Zealand Pharma A/S Obesity R&D Event Transcript

By GuruFocus Research 02-15-2024